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district level. CONCLUSION: This approach seem to be an
original, robust and reproducible technique for risk assessment
purpose, which can be applied to a number of diseases and
technology assessment when the number of indicators (risk indi-
cators, clinical indicators, biologic indicators, etc) make data
interpretation, comparisons and decision making difﬁcult.
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OBJECTIVE: Methicillin-resistant Staphylococcus aureus, or
MRSA, is a commonly acquired infection in the hospital envi-
ronment. We examine data from the National Inpatient Sample
(NIS) to diagnose trends to gain more insight about the infection.
It is the purpose of this study to determine if race, age or gender
are factors in the severity of the infection, and to ascertain what
effects any secondary conditions may have on a patient with
MRSA. METHODS: The data were collected from a 10%
sample from 2004 from the NIS with information relevant to
5974 patients diagnosed with MRSA. The data were then
imported into SAS Enterprise Guide 4. SAS is used to create
tables of data and kernel density estimates, which give an esti-
mate of the data’s probability density, to develop a logistic regres-
sion model relating death risk to speciﬁc diagnoses, and to
develop a linear model concerning a patient’s total charges.
RESULTS: There appears to be a correlation between the age of
a patient and the length of inpatient stay. Asian American and
African American patients experience a higher mortality rate
with MRSA. Total charges were similar between males and
females, although males showed a slightly higher mean; second-
ary conditions and age had a much more pronounced effect on
charges. The three most common conditions present in patients
with MRSA were hypertension, urinary tract infection (UTI), and
congestive heart failure—UTI and heart failure appear to raise
the risk of death to one with MRSA. CONCLUSIONS: Further
studies should be conducted to investigate MRSA and how it
affects people from various ethnic backgrounds and age groups.
By analyzing medical data and performing kernel density esti-
mates, it is possible to uncover important relationships that can
be used to treat patients worldwide.
INFECTION—Cost Studies
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OBJECTIVE: Quantify the budgetary impact of adding a new
carbapenem, doripenem, to a hospital formulary for treatment
of complicated intra-abdominal infection (cIAI), complicated
urinary tract infection (cUTI) and nosocomial pneumonia (NP)
including ventilator-associated pneumonia (VAP), in the United
States. Doripenem has been approved in the US for cIAI and
cUTI and is under FDA review for treatment of NP, including
VAP. METHODS: This model was developed in accordance with
Good Research Practices for Budget Impact Analysis dissemi-
nated by ISPOR to estimate the annual impact on a hospital’s
budget of adding doripenem. Carbapenem (doripenem, imi-
penem, meropenem) wholesale acquisition costs from 2007
National Drug Data File, hospitalization costs (2006 US dollars)
from published literature, annual hospital admissions for NP,
VAP, cIAI, and cUTI, current proportional share of imipenem
and meropenem (50% each, no doripenem use), treatment dura-
tion and length of stay (LOS) from clinical trials were considered.
A new proportional share of 50% doripenem, 30% imipenem
and 20% meropenem was assumed for this analysis. Sensitivity
of results on different proportions of doripenem use was exam-
ined. RESULTS: Total cost per treated patient was estimated to
be $24,284 (range: $13,117 (cUTI) to $71,026 (VAP)), prior to
introduction of doripenem. With the new proportional share, it
would decrease to $23,305 (range: $12,987 (cUTI) to $65,289
(VAP)), a 4% reduction in the budget. Pharmacy costs made up
4% of overall treatment costs. The majority of savings came
from shorter hospital LOS for VAP, observed in clinical trials
comparing doripenem to comparators. Scenarios with a greater
proportion of doripenem use resulted in larger savings to the
hospital budget ($1927 per patient at 100% doripenem use).
Results remained favorable for formulary with doripenem under
various sensitivity analyses. CONCLUSION: Results indicate
that adding doripenem to a hospital formulary will yield poten-
tial savings to a hospital’s budget.
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OBJECTIVE: To quantify the workforce and cost implica-
tions of routine doctor-intensive (DI), nurse-intensive (NI) and
pharmacist-intensive (PI) ART follow-up algorithms for HIV/
AIDS treatment at the Infectious Diseases Institute, a large
urban HIV clinic in Kampala, Uganda. METHODS: We per-
formed a societal perspective cost analysis including health
resource utilization and opportunity cost of patient waiting
(PW) time. A time-motion survey was performed to estimate
median health worker utilization (HWU) and PW times for dif-
ferent services. Unique personnel requirements were identiﬁed
to determine hourly HWU per patient, which was multiplied by
hourly wages for different cadres. PW times were multiplied by
mean hourly wage for Ugandans. National workforce and cost
implications were projected. RESULTS: Median HWU and PW
times per visit (hours) were 0.20 and 0.24 for triage nurses,
0.12 and 1.10 for doctors, 0.08 and 0.27 for pharmacists, and
0.13 and 0.05 for nurses. HWU time for reﬁll pharmacists
was 0.03 with no waiting. Hourly wages were: nurses-$4.6,
doctors-$8.3, and pharmacists-$3.3. The average Ugandan
hourly wage was $0.99. Total annual societal per-patient cost
of follow-up was $45.2 for DI, $28.3 for NI and $16.3 for PI.
Total projected national annual follow-up cost was $13.5
million for DI, $8.5 million for NI and $4.9 million for PI.
Extrapolating to a national level, we project that the substitu-
tion of nurses or pharmacists for doctors would save 404 full-
time-equivalent doctors per year, 18.4% of the current
number practicing in Uganda. CONCLUSION: The use of NI
and PI innovations as substitutes for DI follow-up results in
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